Novo Nordisk A/SNVONYSE
Loading
Cost of Revenue Over TimeExpanding
Percentile Rank100
3Y CAGR+27.1%
5Y CAGR+22.8%
Year-over-Year Change
Direct costs attributable to producing goods sold
3Y CAGR
+27.1%/yr
vs +12.7%/yr prior
5Y CAGR
+22.8%/yr
Recent acceleration
Acceleration
+14.4pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.8x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $58.43B | +31.2% |
| 2024 | $44.52B | +24.5% |
| 2023 | $35.77B | +25.7% |
| 2022 | $28.45B | +20.2% |
| 2021 | $23.66B | +13.0% |
| 2020 | $20.93B | +4.2% |
| 2019 | $20.09B | +14.0% |
| 2018 | $17.62B | -0.1% |
| 2017 | $17.63B | +2.6% |
| 2016 | $17.18B | - |